Anna Mc Laughlin, Dr. rer.nat., MBA

Senior Director, MIDD Consultant

Portrait-of-Anna-Mc-Laughlin_Pharmetheus

Bio

  • Joined Pharmetheus in 2022, actively working in client projects
  • Expertise includes model-informed drug development, model-informed precision dosing, and pharmacometrics in therapeutic areas such as oncology, immuno-oncology, and virology
  • Previously worked as Senior Scientist at Freie Universitaet Berlin, Germany, where she performed pharmacometric research in therapeutic areas such as oncology and immuno-oncology
  • Pharmacist (2017) and Dr.rer.nat. in Pharmacometrics (2021) from Freie Universitaet Berlin, Germany, and MBA (2025) from Trinity College Dublin, Ireland
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Direct and hybrid machine learning approaches do not outperform NLME-based full Bayesian forecasting for early identification of delayed methotrexate eliminationA mechanism-based parsimonious CAR-T cell population PK model and its validation via extension to a population PK-tumor size dynamics model: case study with axicabtagene ciloleucel and brexucabtagene autoleucelDirect and hybrid machine learning approaches do not outperform NLME-based full Bayesian forecasting for early identification of delayed methotrexate eliminationDevelopment of efficient CAR-T cell clinical study designs: Towards understanding of novel anticancer therapies through optimal experimental designA Bayesian-NLME approach identifies patients at risk of delayed MTX elimination if informative TDM data is providedA mathematical viral load model characterises the exposure- response relationship between bulevirtide and hepatitis delta virus and identifies the minimum duration of on-treatment viral load monitoring required for accurate prediction of long-term virologic responsePaediatric pharmacokinetic-pharmacodynamic extrapolation to identify suitable bulevirtide doses for children and adolescents with chronic hepatitis deltaExposure-efficacy analysis of datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, in patients with advanced non-small cell lung cancerModel-informed early clinical development of BI-1808, a novel monoclonal antibody to tumor necrosis factor receptor 2Population pharmacokinetic analysis of Datopotamab deruxtecan (Dato-DXd), a TROP2-targeting antibody-drug conjugateA circular PK/PD/PK model explains the exposure of bulevirtide and bile salts in adult patients with Hepatitis D